Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $41.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 23.94% year-over-year to $41.1 million; the TTM value through Dec 2025 reached $41.1 million, up 23.94%, while the annual FY2025 figure was $41.1 million, 23.94% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $41.1 million in Q4 2025 per LCTX's latest filing, down from $227.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $227.8 million in Q3 2025 to a low of $158725.0 in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $157.8 million, with a median of $169.8 million recorded in 2022.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 109535.84% in 2021 against a maximum downside of 99.89% in 2021.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $164.5 million in 2021, then increased by 3.22% to $169.8 million in 2022, then rose by 1.23% to $171.9 million in 2023, then tumbled by 80.71% to $33.2 million in 2024, then grew by 23.94% to $41.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Shares Outstanding (Weighted Average) are $41.1 million (Q4 2025), $227.8 million (Q3 2025), and $227.2 million (Q2 2025).